Clean Science and Technology Limited reported a consolidated net profit of ₹733.50 million for the quarter ended June 30, 2026, marking a 4.7% sequential increase from the preceding quarter’s profit of ₹582.72 million. The result was underpinned by a 10.5% year-on-year rise in revenue to ₹2,684.32 million and a significant jump in other income. Shareholders are set to receive a final dividend, with payments scheduled for September 30, 2026.

The Board of Directors approved the unaudited standalone and consolidated financial results at its meeting held on August 1, 2026, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Statutory auditors Price Waterhouse Chartered Accountants LLP issued a limited review report on the results, confirming compliance with Ind AS 34 and other generally accepted accounting principles in India.

Financial Performance

Consolidated revenue from operations stood at ₹2,684.32 million in Q1FY27, compared to ₹2,492.53 million in the immediately preceding quarter and ₹2,428.69 million in the same quarter last year. Other income contributed ₹222.18 million, significantly higher than the ₹27.95 million recorded in the prior quarter.

Total expenses rose to ₹1,930.99 million from ₹1,743.61 million in the previous quarter, primarily due to an increase in cost of materials consumed, which jumped to ₹1,268.48 million from ₹991.34 million. Employee benefits expense also increased to ₹166.28 million, up from ₹38.26 million in the prior quarter. The company noted that executive directors had voluntarily forgone a substantial portion of their performance bonus entitlement in the previous quarter, leading to lower employee benefits expense then.

Standalone net profit was reported at ₹732.91 million, with standalone revenue reaching ₹2,071.04 million. Basic earnings per share (EPS) remained constant at ₹6.90 for both consolidated and standalone results.

Strategic Developments and Governance

The Board co-opted Mr. Krishnakumar Satyanarain Saboo as an Additional Director and recommended his appointment as Whole-time Director for a five-year term from August 1, 2026, to July 31, 2031. He will also serve as Factory Occupier effective August 1, 2026. Mr. Saboo, who has over 37 years of experience and has been associated with the company for more than 11 years, currently serves as Group President (Operations).

Additionally, the Board approved the incorporation of a wholly-owned foreign subsidiary in the Netherlands by Clean Fino-Chem Limited, a step-down subsidiary of Clean Science and Technology Limited. The entity, proposed to be named Clean Science BV or similar, will engage in the trading and distribution of specialty chemicals. It is proposed to be incorporated with an initial capital equivalent to EUR 50,000.

The company also highlighted a long-term strategic collaboration entered into by its subsidiary, Clean-Fino Chem Limited, with Geneus Chem AG on July 16, 2026. The agreement involves the exclusive worldwide manufacturing and supply of advanced grades of HALS products. In return, Geneus Chem AG has agreed to issue warrants exercisable within four years, enabling the subsidiary to acquire a 25% stake in Geneus Chem AG on a fully diluted basis upon exercise.

What the Numbers Show

The divergence between revenue growth and expense inflation warrants attention. While consolidated revenue grew 10.5% year-on-year, total expenses surged 19.3% over the same period. This pressure is largely attributable to raw material costs, which rose 36.3% year-on-year to ₹1,268.48 million. However, the company managed to expand profit before tax by 3.2% year-on-year, suggesting that pricing power or mix improvements partially offset input cost inflation. The significant jump in other income, from ₹134.26 million in Q1FY26 to ₹222.18 million in Q1FY27, also provided a tailwind to the bottom line.

The 23rd Annual General Meeting (AGM) is scheduled for September 12, 2026, via Video Conferencing. The record date for determining dividend entitlement is September 5, 2026, with the register of members closing from September 6 to September 12, 2026.

Clean Science and Technology Limited reported a consolidated net profit of ₹733.50 million for the quarter ended June 30, 2026 (Q1FY26), marking a 4.7% decline from ₹700.63 million in the corresponding period of FY25. Despite the dip in bottom-line profitability, the company achieved a 10.5% year-on-year increase in revenue from operations, which stood at ₹2,684.32 million compared to ₹2,428.69 million in Q1FY25. The divergence between revenue growth and profit contraction highlights margin pressure primarily stemming from increased material costs and employee benefits expenses during the quarter.

The Board of Directors approved the unaudited standalone and consolidated financial results at its meeting held on August 1, 2026, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The results were subjected to a limited review by the statutory auditors, Price Waterhouse Chartered Accountants LLP. Additionally, the Board declared a final dividend for equity shareholders, with the record date fixed for September 5, 2026, and payment scheduled for September 30, 2026. The Register of Members will remain closed from September 6 to September 12, 2026, for the purpose of determining dividend entitlements and conducting the 23rd Annual General Meeting (AGM).

Financial Performance Overview

Consolidated total income rose to ₹2,906.50 million from ₹2,562.95 million in Q1FY25, fueled by both operational revenue growth and a significant jump in other income to ₹222.18 million from ₹134.26 million. However, total expenses expanded more sharply to ₹1,930.99 million, up from ₹1,617.46 million in the prior year quarter. Cost of materials consumed increased by 36.3% to ₹1,268.48 million, while employee benefits expense rose 9.3% to ₹166.28 million. The company noted that the lower employee benefits expense in the previous quarter (Q4FY26) was due to executive directors voluntarily foregoing performance bonuses, making the current quarter’s comparison less favorable.

Standalone results showed a net profit of ₹732.91 million, down 4.3% from ₹765.74 million in Q1FY25. Standalone revenue from operations decreased 5.8% to ₹2,071.04 million from ₹2,199.06 million. The standalone other income surged significantly to ₹213.85 million from ₹129.24 million, partially offsetting the decline in core operational revenue.

Strategic Developments and Governance

In a significant strategic move, Clean Fino-Chem Limited, a wholly-owned subsidiary of Clean Science, entered into a long-term collaboration agreement with Geneus Chem AG on July 16, 2026. The partnership involves the manufacturing and exclusive worldwide supply of advanced grades of HALS (Hindered Amine Light Stabilizers) products. Under the terms, Geneus Chem AG will issue warrants to Clean Fino-Chem, exercisable within four years, allowing the subsidiary to acquire a 25% stake in Geneus Chem AG on a fully diluted basis upon exercise.

The Board also co-opted Mr. Krishnakumar Satyanarain Saboo as an Additional Director, effective August 1, 2026. He is recommended for appointment as Whole-time Director for a five-year term ending July 31, 2031, subject to shareholder approval at the upcoming AGM. Mr. Saboo, who has over 37 years of experience in production planning and process improvement, has been associated with the company for more than 11 years and currently serves as Group President (Operations). Additionally, the Board approved the incorporation of a wholly-owned foreign subsidiary in the Netherlands through Clean Fino-Chem Limited, with an initial capital equivalent to EUR 50,000, to engage in the trading and distribution of specialty chemicals.

What the Numbers Show

The financial data reveals a distinct shift in cost structure. While revenue grew robustly at 10.5%, the cost of materials consumed grew at a faster rate of 36.3%, indicating potential input cost inflation or a shift in product mix towards lower-margin items. This was exacerbated by a normalization of employee benefit expenses after the one-time bonus reversal in the preceding quarter. However, the substantial rise in other income (₹222.18 million vs ₹134.26 million) provided a crucial buffer, preventing a sharper decline in net profit. Investors should monitor whether the new HALS product collaboration with Geneus Chem AG can help diversify revenue streams and improve margins in subsequent quarters, as the current standalone revenue contraction suggests headwinds in existing business lines.